期刊文献+

索拉菲尼致手足皮肤毒性反应1例 被引量:4

下载PDF
导出
摘要 1病历摘要患者男,34岁。掌跖斑块伴脱屑2个月,加重半个月,于2017年10月11日来海军军医大学附属长海医院皮肤科就诊。患者2个月前因肝癌肺转移服用印度产甲苯磺酸索拉菲尼0.8 g/d,4 d后掌跖脱屑、硬斑伴口唇干裂,停药2 d后好转。16 d前改德国产甲苯磺酸索拉菲尼(多吉美)0.8 g/d,4 d后出现双侧掌跖红斑、脱屑,黄色斑块及脓疱,伴关节活动受限、行走疼痛,无瘙痒、麻木和局部渗液,颜面出现对称性红色斑片,口唇肿胀、干裂。发病来体力较差,半个月体重减轻2.5 Kg。既往史:肝癌肺转移,病毒性肝炎30余年,肝癌TACE术后。
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2019年第12期758-759,共2页 Journal of Clinical Dermatology
  • 相关文献

参考文献2

二级参考文献31

  • 1Ding SJ,Li Y,Tan YX,et al.From proteomic analysis to clinical sig-nificance:overexpression of cytokeratin 19 correlates with hepato-cellular carcinoma metastasis[J].MolCell Proteomics,2004,3(1):73-81.
  • 2Altekruse SF,McGlynn KA,Reichman ME.Hepatocellular carcino-ma incidence,mortality,and survival trends in the United Statesfrom 1975 to 2005[J].J ClinOncol,2009,27(9):1485-1491.
  • 3Rimassa L,Santoro A.Sorafenib therapy in advanced hepatocellu-lar carcinoma:the SHARP trial[J].Expert Rev Anticancer Ther,2009,9(6):739-745.
  • 4Cheng AL,Kang YK,Chen Z,et al.EfEcacy and safety of sorafenibin patients in the Asia-Pacific region with advanced hepatocellularcarcinoma:a phase IH randomized,doubled-blind,placebo-con-trolled trial[J].Lancet Oncol,2009,10(1):25-34.
  • 5Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibitsbroad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and targets the RAF/MEK/ERK pathway and recep-tor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
  • 6Carlomagno F,Anaganti S,Guida T,et al.BAY 43-9006 inhibi-tion of oncogenic RET mutants[J].J Natl Cancer Inst,2006,98(5):326-334.
  • 7Escudier B,Eisen T,Stadler WM,et al.Sorafenib in advancedclear-cell renal-cell carcinoma[J].N EnglJ Med,2007,356(2):125-134.
  • 8Yang CH,Lin WC,Chuang CK,et al.Hand-foot skin reaction inpatients treated with sorafenib:a clinicopathologicalstudyof cutane-ous manifestations due to multi targeted kinase inhibitor therapy[J].BrJ Dermatol,2008,158(3):592-596.
  • 9Beldner M,Jacobson M,Burges GE,et al.Localized palmar-plan-tar epidermal hyperplasia:a previously undefined dermatologic tox-icity to sorafenib[J].Oncologist,2007,12(10):1178-1182.
  • 10Azad NS,Aragon-ChingJB,Dahut WL,et al.Hand-foot skin reac-tion increases with cumulative sorafenib dose and with combinationanti-vascular endothelial growth factor therapyJ].Clin CancerRes,2009,15(4):1411-1416.

共引文献34

同被引文献44

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部